N,N'-bisgalloyl 1,3-diaminopropane,

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N,N'-bisgalloyl 1,3-diaminopropane,
• 英文别名: N,N'-1,3-propanediylbis(3,4,5-trihydroxybenzamide)；N,N''-1,3-Propanediylbis(3,4,5-trihydroxybenzamide)Hydrate；3,4,5-trihydroxy-N-[3-[(3,4,5-trihydroxybenzoyl)amino]propyl]benzamide
• 化学式: C₁₇H₁₈N₂O₈
• 分子量: 378.339
• InChiKey: LLUICHYMAUMIIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  180
• 氢给体数：
  8
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3,4,5-三甲氧基苯甲酸 在 五氯化磷 、 三溴化硼 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 N,N'-bisgalloyl 1,3-diaminopropane,
  参考文献：
  名称：

  Synthesis and in Vitro Evaluation of Two Progressive Series of Bifunctional Polyhydroxybenzamide Catechol-O-methyltransferase Inhibitors

  摘要：

  Two progressive series of molecules with two polyhydroxybenzamide substructures were synthesized and tested as potential inhibitors of catechol-O-methyltransferase (COMT). These compounds were designed for the purpose of enhanced enzyme binding with duplicated substructures separated by a linker section of various lengths. Our results show that potency and mode of inhibition observed with the ''bifunctional'' compounds were a reflection of their bifunctional nature. Furthermore, potency and mode of inhibition were dependent on the length of the linker section. Of the assayed compounds, the optimum linker was found to be diaminopropane. For example, N,N'-1,3-propanediylbis(3,4-dihydroxybenzamide) and N,N'-1,3-propanediylbis(3,4,5-trihydroxybenzamide) demonstrated strong inhibitory action against COMT, with apparent K-i values of 0.3 and 6.0 mu M, respectively.

  DOI：

  10.1021/jm9605187

文献信息

• Simple, Clean and Highly Efficient Synthesis of Polyphenolic Amides Catalysed by Ferric Exchanged Montmorillonite
  作者：Dhrubajyoti Mahanta、Jyotirekha G. Handique

  DOI：10.2174/157017811799304241

  日期：2011.11.1

  A mild, efficient and highly convenient protocol is reported for the synthesis of a series of polyphenolic amides using ferric exchanged montmorillonite as a strong solid acid catalyst. This heterogeneous catalyst has an advantage of a strikingly simple work up procedure over conventional homogeneous acids. The catalyst is recoverable and recyclable.

  报告采用铁交换蒙脱石作为强固酸催化剂，合成了一系列多酚酰胺，该方法温和、高效、操作简便。与传统的均相酸催化剂相比，这种异相催化剂的优点是操作过程非常简单。催化剂可回收和循环使用。
• Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism
  申请人：Lawrence Daniel A.

  公开号：US20100137194A1

  公开（公告）日：2010-06-03

  The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.

  本发明涉及纤溶酶原激活剂-1（PAI-1）抑制剂化合物及其在治疗任何与升高的PAI-1相关的疾病或病状中的应用。本发明包括但不限于使用这些化合物来调节脂质代谢并治疗与升高的PAI-1、胆固醇或脂质水平相关的病症。
• PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20160009748A1

  公开（公告）日：2016-01-14

  The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.

  本发明涉及纤溶酶原激活物-1（PAI-1）抑制剂化合物及其在治疗与升高的PAI-1相关的任何疾病或病况中的用途。本发明包括但不限于使用这样的化合物来调节脂质代谢并治疗与升高的PAI-1、胆固醇或脂质水平相关的病症。
• Dimeric polyphenols to pave the way for new antimalarial drugs
  作者：Gilles Degotte、Hélène Pendeville、Carla Di Chio、Roberta Ettari、Bernard Pirotte、Michel Frédérich、Pierre Francotte

  DOI：10.1039/d2md00392a

  日期：——

  Because of the threat of resistant Plasmodium sp., new orally active antimalarials are urgently needed. Inspired by the structure of ellagic acid, exhibiting potent in vivo and in vitro antiplasmodial effects, polyphenolic structures possessing a similar activity-safety profile were synthesized. Indeed, most exhibited a marked in vitro effect (IC50 < 4 μM) on resistant P. falciparum, without any detrimental

  由于耐药疟原虫的威胁。 ，迫切需要新的口服活性抗疟药。受鞣花酸结构的启发，在体内和体外表现出有效的抗疟原虫作用，合成了具有相似活性-安全性的多酚结构。事实上，大多数药物对恶性疟原虫具有显着的体外作用（IC 50 < 4 μM），而在毒性测定（溶血、细胞毒性、体内）期间没有报告任何有害作用。此外，与鞣花酸相比，它们具有更高的水溶性（从 7 μM 到 2.7 mM）。其中， 30是最有希望用于抗疟用途的，因为与口服无效的鞣花酸相比，其在小鼠口服给药（50 mg kg -1 ）后显示出显着的寄生虫血症减少。总之，我们的研究发现了一种有前途的支架，这可以为疟疾治疗带来新的见解。
• US9120744B2
  申请人：——

  公开号：US9120744B2

  公开（公告）日：2015-09-01